mothers2mothers (m2m) is delighted to announce that Colin Freund, CEO of Modra Pharmaceuticals, has been appointed Chair of the m2m U.S. Board of Directors. A member of m2m’s U.S. Board since June 2018, Colin replaces m2m Founder Dr. Mitch Besser as Board Chair.
“We are fortunate to have Colin’s leadership and expertise at this exciting time of growth at mothers2mothers,” said Frank Beadle de Palomo, m2m’s President and CEO. “In pursuit of our vision of health, hope, and an HIV-free future, we are expanding our footprint and depth of programming, including starting to work in four new countries. We have also recently begun to provide clinical services for the first time in our 19-year history. Colin’s many years of experience leading innovative companies in the healthcare space will provide invaluable guidance in helping us reach our strategic goals,” Frank added.
Colin has over 20 years of experience in the pharmaceutical and biotechnology industries, with a primary focus on oncology. Since December 2018, he has led Modra Pharmaceuticals, a company focused on the development of oral chemotherapies that aim to improve the outcomes and quality of life for cancer patients, while also reducing the burden on healthcare systems. Before that, Colin was CEO of QUE Oncology, Inc., held senior management positions at Transgene SA and GPC Biotech AG, and was a project leader at the Boston Consulting Group.
“mothers2mothers’ peer mentor approach to critical healthcare issues, whereby it trains and employs women living with HIV as frontline health workers in the community, is an amazing initiative with measurable, game-changing results. This model can help build capacity in sub-Saharan Africa’s critically understaffed health systems, create better health outcomes for families, and provide a valuable source of economic empowerment for women. I am excited to work closely with the organisation’s leadership as m2m grows its reach and impact even further,” said Colin.
Colin received his M.A. in Economics and Management Studies from the University of Cambridge, U.K., and his M.B.A. from Stanford University, U.S.
For more information on m2m’s Leadership and structure, please visit: https://m2m.org/who-we-are/